Skip to content
Black Week: 20% off everything, code BLACK

Search

What are you looking for?

Type at least 2 characters to see suggestions.

Fat Loss and Metabolism Marek Wawrzyk

SR-9011 – a unique fat burner

SR-9011 is indeed different from other compounds in this category, although not for the reason it is sometimes recommended.

SR-9011 - a unique fat burner

SR-9011 is indeed different from other compounds in this category, although not for the reason it is sometimes recommended. What sets it apart is that published work has questioned its declared mechanism of action – it has been shown that its related SR-9009 produces metabolic effects also where the receptor to which they are attributed is absent. This is quite an unusual situation for a compound described as “precisely acting on the biological clock.” This article discusses the mechanism, data, and what is not known about SR-9011 – and much more is not known than the popular narrative suggests.

All substances discussed in the article are of research nature and are not intended for human consumption. The description of their action is based solely on laboratory test results and experimental observations, not on clinical tests.

What SR-9011 is – and what it isn’t

SR-9011 is a synthetic molecule described as an agonist of the REV-ERB receptor – a nuclear receptor involved in the regulation of circadian rhythm and metabolism. It was created in the same research program as the related SR-9009 (stenabolic), with which it shares the mechanism and most of the literature.

Let’s start with the classification order, because in common usage this compound is sometimes placed in the wrong group:

Relationship What it is NOT What is DEFECT
SR-9011 / SR-9009 is not a SARM REV-ERB agonist – metabolic modulator S4.4
GW-501516 (cardarine) is not a SARM PPARδ agonist – metabolic modulator S4.4
MK-677 (ibutamoren) is not a SARM growth hormone secretagogue S2
Ostarine, LGD-4033, RAD-140 — proper SARMs – androgen receptor ligands S1.2

SR-9011 does not bind the androgen receptor and has nothing to do with the SARM mechanism. The full classification of this group is discussed in the material about SARM for bodybuilders. It is also not a dietary supplement – it is a research-grade compound without marketing authorization in any jurisdiction.

REV-ERB – biological clock mechanism

REV-ERB (α and β isoforms) are nuclear receptors acting as transcriptional repressors – unlike most receptors of this family, they do not activate gene expression, but silence it. They are part of the feedback loop of the circadian clock, regulating, among other things, the expression of the Bmal1 gene.

Because the same molecular clock controls the rhythm of metabolic processes – hepatic lipid metabolism, glucose metabolism, mitochondrial activity in muscle – pharmacological effects on REV-ERB were considered as a way to modulate metabolism. The role of REV-ERB in the regulation of sleep and wakefulness was studied separately (Amador et al., 2016, PMID 27603791).

Where its popularity came from: a 2012 study

The entire narrative around this group of compounds comes from one publication. A paper published in Nature in 2012 described synthetic REV-ERB agonists — SR-9009 and SR-9011 — and their effects on circadian behavior and metabolism (Solt et al., 2012, PMID 22460951). Among other things, changes in energy expenditure and fat tissue mass were observed.

The study was conducted in mice. This is the only source for the “metabolism-accelerating” claims repeated in the SR-9011 materials – and it concerns an animal model, not humans.

Problem: effects independent of REV-ERB

Here we come to the essence that distinguishes this relationship from the others described in this category.

A study published in PNAS in 2019 examined whether the effects of SR-9009 were actually mediated by the REV-ERB receptor. Cells lacking this receptor were used for this purpose. Result: SR-9009 caused effects on cell proliferation and metabolism also in their absence – i.e. regardless of the molecular target to which these effects were attributed (Dierickx et al., 2019, PMID 31127047).

The consequences are more serious than they seem at first glance:

  • The description of the mechanism requires revision. The entire narrative of “precise regulation of the biological clock” is based on the assumption that the compound acts through REV-ERB. Since it also works without it, the actual mechanism remains undetermined.
  • Predicting effects becomes more difficult. If it is not known through what molecular target a compound acts, it is impossible to predict its full action profile or spectrum of interactions.
  • The safety assessment loses its reference point. The argument “it acts selectively on one receptor, so it is predictable” is no longer valid.

It is worth noting that REV-ERB agonists also show significant cellular activity in other contexts: a study published in Nature showed that pharmacological activation of REV-ERB is lethal for cancer cells and cells in a state of oncogene-induced senescence (Sulli et al., 2018, PMID 29320480). In the oncological context, this is a promising observation – but at the same time it shows that we are talking about compounds with a significant impact on cell survival, and not inert metabolism modulators.

What the data show, and what they do not

The state of evidence for SR-9011 can be summarized briefly because it is poor.

  • No clinical trials in humans. There have been no published studies assessing the efficacy or safety of SR-9011 in humans, either first- or later-stage studies.
  • No pharmacokinetic data in humans. It is not known how the compound behaves when administered to humans.
  • No long-term safety data. None available for any time horizon.
  • Evidence limited to animal and cellular models, some of which – as described above – calls into question the claimed mechanism.

In practice, this means that claims about “improving metabolic health”, “lowering LDL cholesterol” or “regulating glucose” in humans are not supported by research. Observations of this type come from a mouse model from 2012.

Separately, it is worth disarming the most frequently repeated argument: “it does not have a stimulating effect, so it is safe”. This inference is not correct. The lack of central nervous system stimulation only means that this particular group of symptoms will not occur – it does not say anything about the action at the cellular level. The paper describing the lethal effect of REV-ERB agonists on cells (PMID 29320480) clearly shows why the absence of subjective symptoms is not a measure of safety.

Harm reduction

  • The safety profile in humans does not exist. It is not “favorable” or “unfavorable” – it simply has not been established because studies have not been done.
  • The mechanism remains undetermined. Due to the demonstrated effects independent of REV-ERB, it is impossible to predict the full spectrum of action or interaction with other substances.
  • Combination with other compounds multiplies the unknowns. A case of poisoning after simultaneous exposure to two metabolic modulators – GW1516 and ostarine – has been described with full clinical and analytical documentation (Kintz et al., 2021, PMID 34678947).
  • Modulation of the circadian clock is not local. The circadian rhythm regulates processes in many organs simultaneously, so interference with it is by definition not limited to the metabolism of adipose tissue.

Regulatory status and anti-doping notice

SR-9011 is not registered as a medicinal product in any jurisdiction. It is not a dietary supplement or food and is not subject to health claims. There is no entity authorized to issue recommendations regarding its use in humans – and a research-reagent supplier is not such an entity.

WADA Status: Category S4.4 – Metabolic Modulators. This section covers PPARδ agonists and AMPK kinase activators and related metabolic modulators. Relationships in this category are prohibited at all times—inside and outside the competition period.

Anti-doping regulations are not limited to professionals: in Poland, the Prohibited List is in force through the Polish Anti-Doping Agency (POLADA), and amateur competitors taking part in competitions covered by these regulations are also subject to control. Because SR-9011 is not a registered drug, there is no path to obtain a therapeutic use exemption (TUE). The current status should be verified each time in the applicable version of the Prohibited List.

What’s actually in the product

In addition to the mechanistic uncertainty, there is the issue of compliance of the composition with the label. The analysis published in JAMA examined 44 products sold online as SARMs. Only 52% contained any SARM, and 39% contained another unapproved drug — these explicitly listed SR9009 along with ibutamoren and GW501516. No active compound was detected in 9% of the products, and the compliance of the declared amount with the actual amount was found only in 41% of cases (Van Wagoner et al., 2017, PMID 29183075).

For a controlled competitor, this means the risk of violating the regulations with a substance that he did not consciously choose. The only document determining the identity of the material is the certificate of analysis assigned to a specific batch.

Frequently asked questions

Is SR-9011 a SARM?

No. SARMs are androgen receptor ligands; SR-9011 is described as an agonist of the REV-ERB nuclear receptor, which regulates circadian rhythm and metabolism. On the WADA Prohibited List, it is listed in category S4.4, not S1.2 appropriate for SARMs.

Does SR-9011 really act on the biological clock?

The declared mechanism is based on REV-ERB agonism, but a study published in PNAS showed that the related SR-9009 also causes metabolic effects in cells lacking this receptor (PMID 31127047). The actual mechanism therefore remains undetermined.

Does the lack of a stimulating effect mean it is safe?

No. It only means the absence of this particular group of symptoms. It says nothing about action at the cellular level – and REV-ERB agonists show significant activity on cell survival (PMID 29320480).

Are there studies of SR-9011 in humans?

There have been no published clinical trials assessing the effectiveness or safety of this compound in humans. Available data are from animal and cell models.

Why doesn’t the article provide doses?

Because SR-9011 does not have the status of a medicinal product and has not gone through the registration process in which dosages are determined. A research-reagent supplier is not authorized to issue recommendations for use in humans.

Summary

SR-9011 is an investigational grade compound described as a REV-ERB receptor agonist – it is not a SARM or dietary supplement and is not approved for marketing in any jurisdiction. It owes its popularity to a single publication from 2012, in which the effect of REV-ERB agonists on energy expenditure and fat tissue mass was observed in mice. Subsequent work published in PNAS, however, showed that the related SR-9009 also causes metabolic effects in cells lacking the REV-ERB receptor – which means that the claimed mechanism does not explain the observed effect, and the actual one remains undetermined. No human clinical trials have been published for SR-9011: no data on efficacy, pharmacokinetics or safety. The argument about lack of stimulatory effect is not an argument for safety – it concerns one group of symptoms, not a cellular effect. The association is on the WADA Prohibited List in category S4.4 and is prohibited at all times, including for amateur athletes covered by POLADA regulations.

Product documentation

Product pages for research materials, together with batch analytical documentation are available in the SARMs and modulators category. We discuss the broader context of the mechanisms of this group of compounds in the effective fat burners guide. Materials intended for research use only.

Bibliography

  1. Solt LA, Wang Y, Banerjee S, et al. Regulation of circadian behavior and metabolism by synthetic REV-ERB agonists. Nature. 2012;485(7396):62-68. PMID: 22460951
  2. Dierickx P, Emmett MJ, Jiang C, et al. SR9009 has REV-ERB-independent effects on cell proliferation and metabolism. Proc Natl Acad Sci U S A. 2019;116(25):12147-12152. PMID: 31127047
  3. Sulli G, Rommel A, Wang X, et al. Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence. Nature. 2018;553(7688):351-355. PMID: 29320480
  4. Amador A, Huitron-Resendiz S, Roberts AJ, et al. Pharmacological Targeting the REV-ERBs in Sleep/Wake Regulation. PLoS One. 2016;11(9):e0162452. PMID: 27603791
  5. Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA. 2017;318(20):2004-2010. PMID: 29183075
  6. Kintz P, Gheddar L, Paradis C, et al. Peroxisome Proliferator-Activated Receptor Delta Agonist (PPAR-delta) and Selective Androgen Receptor Modulator (SARM) Abuse: Clinical, Analytical and Biological Data in a Case Involving a Poisonous Combination of GW1516 (Cardarine) and MK2866 (Ostarine). Toxics. 2021;9(10):251. PMID: 34678947
  7. Weihrauch M, Handschin C. Pharmacological targeting of exercise adaptations in skeletal muscle: Benefits and pitfalls. Biochem Pharmacol. 2018;147:211-220. PMID: 29061342
  8. Narkar VA, Downes M, Yu RT, et al. AMPK and PPARdelta agonists are exercise mimetics. Cell. 2008;134(3):405-415. PMID: 18674809
  9. Vignali JD, Pak KC, Beverley HR, et al. Systematic Review of Safety of Selective Androgen Receptor Modulators in Healthy Adults: Implications for Recreational Users. J Xenobiot. 2023;13(2):218-236. PMID: 37218811